| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (replaced TA289) |
|
Medicine details |
|
| Medicine name | ruxolitinib (Jakavi®) |
| Formulation | 5 mg, 15 mg, 20 mg tablet |
| Reference number | 1356 |
| Indication | Treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/07/2012 |
| NICE guidance | |